New antibody treatment combined with chemotherapy for advanced lung cancer

Plain-English translation of NCT07098988 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called combined with three standard cancer drugs (pembrolizumab, pemetrexed, and carboplatin) to treat people with newly diagnosed advanced lung cancer. Half of the participants will receive plus the standard treatment, while the other half will receive a placebo (fake medication) plus the same standard treatment. Researchers want to see if adding this new medication helps patients live longer and shrink their tumors.

Advanced lung cancer is a serious disease that is difficult to treat, and current standard treatments don't work well enough for everyone. This trial is exploring whether this new antibody treatment can boost the effectiveness of existing chemotherapy and immunotherapy to help more patients.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with stage IV (advanced) non-squamous lung cancer that has spread
your cancer does not have certain genetic mutations (like EGFR or ALK) that would require different targeted drugs
you have measurable tumors that can be seen on imaging scans
you have not received any prior chemotherapy or immunotherapy for advanced lung cancer (though prior treatments completed at least 12 months ago may be okay)
you are 18 years or older and in good enough overall health to tolerate chemotherapy (ECOG performance status 0-1)
you have a tissue biopsy available and are willing to provide it for research purposes

You likely don't qualify if…

your lung cancer is predominantly squamous cell or small cell type
you have had a heart attack, liver failure, kidney failure, or other major organ damage within the last 3 months
you had major surgery within the last 4 weeks
you have active inflammatory bowel disease, diverticulitis, or a bowel obstruction
you have cancer in your brain or history of another cancer within the last 5 years

What participation looks like

If you join this trial, you will receive intravenous infusions (through an IV) every 3 weeks at a research hospital or clinic. You'll get either the new medication or a placebo along with three standard chemotherapy drugs. The chemotherapy portion lasts 4 cycles (about 12 weeks), while the other treatments continue for up to 35 cycles (about 2 years). You'll have regular blood tests, imaging scans, and checkups to monitor how you're doing and whether the treatment is working.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

New antibody treatment combined with chemotherapy for advanced lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations